EUVIMEDEUVIMED entdecken
Crossref

A novel KCNC1 gain‐of‐function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine

Paolo Ambrosino iD, Francesca Ragona iD, Ilaria Mosca, Chiara Vannicola, Laura Canafoglia iD, Roberta Solazzi iD, Ilaria Rivolta, Elena Freri iD, Tiziana Granata iD, Giuliana Messina iD, Barbara Castellotti iD, Cinzia Gellera iD und 3 weitere

Epilepsia · 2023

DOI: 10.1111/epi.17656 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, 2023. Verfasst von Paolo Ambrosino und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Science and Technology, University of Sannio, Benevento, Italy. Hauptthemen laut MEDLINE: Epilepsies, Myoclonic, Seizures, Febrile. Die Arbeit wurde bisher 23-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: Ministero della Salute, Ministero dell’Istruzione, dell’Università e della Ricerca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Variable phenotypes, including developmental encephalopathy with (DEE) or without seizures and myoclonic epilepsy and ataxia due to potassium channel mutation, are caused by pathogenetic variants in KCNC1 , encoding for Kv3.1 channel subunits. In vitro, channels carrying most KCNC1 pathogenic variants display loss‐of‐function features. Here, we describe a child affected by DEE with fever‐triggered seizures, caused by a novel de novo heterozygous missense KCNC1 variant (c.1273G>A; V425M). Patch‐clamp recordings in transiently transfected CHO cells revealed that, compared to wild‐type, Kv3.1 V425M currents (1) were larger, with membrane potentials between −40 and +40 mV; (2) displayed a hyperpolarizing shift in activation gating; (3) failed to inactivate; and (4) had slower activation and deactivation kinetics, consistent with a mixed functional pattern with prevalent gain‐of‐function effects. Exposure to the antidepressant drug fluoxetine inhibited currents expressed by both wild‐type and mutant Kv3.1 channels. Treatment of the proband with fluoxetine led to a rapid and prolonged clinical amelioration, with the disappearance of seizures and an improvement in balance, gross motor skills, and oculomotor coordination. These results suggest that drug repurposing based on the specific genetic defect may provide an effective personalized treatment for KCNC1 ‐related DEEs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Epilepsies, MyoclonicSeizures, FebrileCricetinaeAnimalsFluoxetineCricetulusPrecision MedicineGain of Function MutationSeizures

Stichwörter der Autor:innen

KCNC1drug repurposingepilepsyfluoxetinenext generation sequencingprecision medicine

Substanzen

Fluoxetine

Autor:innen und Institutionen

  • Department of Science and Technology, University of Sannio, Benevento, Italy.
  • Department of Pediatric Neuroscience, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.
  • Department of Medicine and Health Science, University of Molise, Campobasso, Italy.
  • Department of Diagnostic and Technology, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.
  • School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy.
  • Unit of Genetics of Neurodegenerative and Metabolic Diseases, Fondazione IRCCS Istituto Neurologico C. Besta, Milan, Italy.

ORCID-Profile: Paolo Ambrosino, Francesca Ragona, Laura Canafoglia, Roberta Solazzi, Elena Freri, Tiziana Granata, Giuliana Messina, Barbara Castellotti, Cinzia Gellera, Maria Virginia Soldovieri, Jacopo Cosimo DiFrancesco, Maurizio Taglialatela

Förderung

  • Ministero della Salute
  • Ministero dell’Istruzione, dell’Università e della Ricerca

Zitieren

APA

Ambrosino, P., Ragona, F., Mosca, I., Vannicola, C., Canafoglia, L., Solazzi, R., Rivolta, I., Freri, E., Granata, T., Messina, G., Castellotti, B., Gellera, C., Soldovieri, M. V., DiFrancesco, J. C., & Taglialatela, M. (2023). A novel KCNC1 gain‐of‐function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine. Epilepsia. https://doi.org/10.1111/epi.17656

Vancouver

Ambrosino P, Ragona F, Mosca I, Vannicola C, Canafoglia L, Solazzi R, et al. A novel KCNC1 gain‐of‐function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine. Epilepsia. 2023. doi:10.1111/epi.17656

BibTeX
@article{Ambrosino2023,
  author = {Ambrosino, Paolo and Ragona, Francesca and Mosca, Ilaria and Vannicola, Chiara and Canafoglia, Laura and Solazzi, Roberta and Rivolta, Ilaria and Freri, Elena and Granata, Tiziana and Messina, Giuliana and Castellotti, Barbara and Gellera, Cinzia and Soldovieri, Maria Virginia and DiFrancesco, Jacopo Cosimo and Taglialatela, Maurizio},
  title = {A novel KCNC1 gain‐of‐function variant causing developmental and epileptic encephalopathy: “Precision medicine” approach with fluoxetine},
  journal = {Epilepsia},
  year = {2023},
  doi = {10.1111/epi.17656}
}
Kostenlos starten →